Prior to the discovery of β2-adrenergic receptor (β2-AR)-agonists influencing FSHD pathogenesis, several trials with β2-AR like clenbuterol or salbutamol had been conducted due to their anabolic effects [134–136]. Here, ADRB2 is linked to facioscapulohumeral muscular dystrophy.